ABSTRACT OBJECTIVES This study sought to examine the feasibility, safety, and intermediate-term outcomes in patients undergoing percutaneous transvenous transcatheter mitral valve implantation in failed bioprosthesis, ring annuloplasty, and calcific mitral stenosis.
and carries a higher procedural mortality (3, 4) . Transcatheter valve-in-valve implantation is a promising therapy for such patients, with emerging evidence suggesting excellent feasibility of this approach (5) (6) (7) . Although a less invasive treatment, transcatheter mitral valve-in-valve procedures pose several challenges including lack of direct visualization of the valve during deployment and lack of direct fixation of the valve prosthesis using sutures. As such, accurate pre-procedural planning taking into account appropriate access site and valve size is critical in an often elderly and frail population. Eleid et al.
Transvenous Transseptal Mitral Valve Implantation (Bottom right) with or without rapid ventricular pacing the valve is deployed until slight flaring is achieved at stent ends.
Eleid et al. During deployment, the SAPIEN valve was expanded to achieve mild flaring of the ends of the valve stent on the ventricular and atrial sides. Eleid et al.
Transvenous Transseptal Mitral Valve Implantation Table 1 . Procedural characteristics are shown in Table 2 . Median number of postprocedure hospital days was 2 days with 16 (33%) requiring time in the intensive care unit. Fifteen (31%) patients were dismissed from the hospital the day after the procedure and 10 (21%) patients were discharged 2 days after the procedure. Values are mean AE SD or n (%).
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; STS ¼ Society of Thoracic Surgeons. Atrial septal defect closure performed 3 (6) Values are n (%) or mean AE SD.
Eleid et al.
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Transvenous Transseptal Mitral Valve Implantation Table 5 Table 6 ). There was also a significant reduction in the total procedure duration between these 2 groups (114 AE 28 min vs. 86 AE 30 min; p ¼ 0.05).
THIRTY-DAY FOLLOW-UP. Thirty-day survival free of death and cardiovascular surgery was 85% in the overall group and 91% in the failed bioprosthetic mitral valve subgroup. One patient (29-mm SAPIEN XT in 31-mm Hancock II; Medtronic, Minneapolis, Minnesota) developed prosthetic valve thrombosis that manifested as increased prosthesis gradients while on therapeutic anticoagulation with warfarin and was diagnosed using TEE demonstrating leaflet thickening and reduced leaflet motion. The valve thrombosis was successfully treated with increasing the target international normalized ratio range to 3.0 to 3.5 ( Table 7) .
As mentioned previously, 1 patient that underwent mitral valve-in-ring procedure had dynamic LV outflow tract obstruction that was successfully managed with increased hydration, and another required an elective surgical resection of the anterior Another notable aspect of the data presented here is the high prevalence of patients (52%) that were discharged from the hospital 1 to 2 days after percutaneous mitral valve implantation, which highlights the minimally invasive nature of this procedure and the potential for substantially improved patient satisfaction, recovery time and hospitalization costs.
At 30-day follow-up the majority of patients were NYHA functional class I to II, prosthesis function remained stable and there was further reduction in pulmonary hypertension compared to immediately post-procedure. Warfarin was prescribed for all patients prior to hospital discharge due to concern over the potential risk of late valve thrombosis. The optimal adjunctive antiplatelet and antithrombotic therapy is unknown for patients undergoing mitral valve-in-valve implantation, and longer-term followup will be needed to address this question.
Our results also show promise for this technique in patients with complete mitral rings, although the success rate was lower and complication rate higher in these patients. In patients with pre-existing Values are n (%) or mean AE SD. *All patients prior to procedural modifications. †All patients after procedural modifications.
VIV ¼ valve-in-valve. Values are n (%).
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